Elevated calprotectin in patients with atrial fibrillation with and without heart failure
| Autor: | Bo Løfgren, Hans Rickers, Leif F. Bach, Laerke Valsøe Bruhn, Nete Hornung, Anders S Schmidt, Kasper G Lauridsen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Clinical Biochemistry Electric Countershock Gene Expression 030204 cardiovascular system & hematology Cardioversion 03 medical and health sciences fluids and secretions 0302 clinical medicine Internal medicine Atrial Fibrillation Medicine Humans In patient 030212 general & internal medicine Myocardial infarction Aged Heart Failure business.industry Unstable angina Atrial fibrillation General Medicine Middle Aged medicine.disease C-Reactive Protein Heart failure Case-Control Studies Direct current cardioversion Cardiology Female Calprotectin business Leukocyte L1 Antigen Complex |
| Zdroj: | Bruhn, L V, Lauridsen, K G, Schmidt, A S, Rickers, H, Bach, L F, Løfgren, B & Hornung, N 2017, ' Elevated calprotectin in patients with atrial fibrillation with and without heart failure ', Scandinavian Journal of Clinical & Laboratory Investigation, vol. 77, no. 3, pp. 210-215 . https://doi.org/10.1080/00365513.2017.1292364 |
| DOI: | 10.1080/00365513.2017.1292364 |
| Popis: | Calprotectin is an inflammatory marker, which has been found elevated in patients suffering from cardiac conditions, e.g. myocardial infarction, unstable angina and chronic heart failure. Inflammation has further been linked to atrial fibrillation (AF). However, the association between calprotectin and AF is unknown. We aimed to compare calprotectin levels in patients suffering from AF with healthy adults. In addition, AF patients with and without heart failure were compared. Calprotectin was measured in patients undergoing elective direct current cardioversion for AF. Calprotectin was determined before, 4 hours and 3 months after cardioversion. Healthy blood donors were used to verify the reference interval for calprotectin. In total, 104 prospectively enrolled patients were included. The median serum calprotectin level for AF patients was 1.6 μg/mL before cardioversion. Calprotectin levels increased significantly 4 h (1.9 μg/mL) and 3 months (2.2 μg/mL) after cardioversion. Blood donors' median serum calprotectin (1.3 μg/mL) was significantly lower than AF patients. AF patients with heart failure had significantly higher calprotectin at baseline compared with AF patients without a history of heart failure (2.0 μg/mL vs. 1.5 μg/mL). The difference was not significant at 4 h (2.0 μg/mL vs. 1.7 μg/mL) or 3 months (2.5 μg/mL vs. 2.2 μg/mL). In conclusion, the calprotectin levels in patients with AF were significantly higher than healthy blood donors and were further increased after cardioversion. AF patients with heart failure had significantly higher levels of calprotectin than AF patients without heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|